Table 1. Characteristics of selected and non-selected participants per study site.
| Bangladesh | Indonesia | Ethiopia | ||||
|---|---|---|---|---|---|---|
| Excluded cohort | Selected Cohort | Excluded cohort | Selected Cohort | Excluded cohort | Selected Cohort | |
| Number | 94 | 87 | 591* | 75 | 201 | 173 |
| Females (%) | 21 (22.3) | 25 (28.7) | 312 (52.8) | 35 (46.7) | 98 (49.5) | 78 (45.1) |
| P.falciparum (%) | 61 (64.9) | 54 (62.1) | 313 (52.3) | 38 (50.7) | 0 (0.0) | 0 (0.0) |
| P.vivax (%) | 26 (27.7) | 29 (33.3) | 261 (46.7) | 37 (49.3) | 198 (100.0) | 173 (100.0) |
| Mixed infection (%) | 7 (7.4) | 4 (4.6) | 24 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Geometric mean (95% of range) parasite density for P.falciparum and mixed infections | 3,924 (80–80,000) | 8,903 (80–960,000) | 4,532 (200–76,000) | 5,314 (360–84,000) | - | - |
| Geometric mean parasite density (per μl) (95% of range) for P.vivax | 2,920 (360–26,600) | 2,507 (80–28,720) | 3,796 (160–36,000) | 2,236 (80–18,440) | 15,433 (889–167,500) | 9,143 (667–117,500) |
| Geometric mean parasite density (per μl) (95% of range) for mixed infections | 6,124 (200–460,000) | 24,878 (667–185,000) | 894 (0–1,040) | 0 (0–0) | - | - |
| Mean Hb in g/dL (95%CI) on day of enrolment | 12.5 (12.1–12.9) | 12.8 (12.3–13.3) | 11.9 (11.8–12.1) | 12.6 (11.9–13.2) | 13.2 (13.0–13.4) | 13.3 (13.0–13.4) |
| Median G6PD activity at enrolment in U/gHb (IQR) | 8.8 (8.3–9.5) | 7.5 (6.2–9.5) | - | 10.3 (9.7 to 10.9) | 10.8 (9.3–12.2) | 11.5 (10.6 to 12.8) |
| 100% G6PD activity (in U/gHb)** | 7.03 | 9.24 | 12.13 | |||
*the clinical trial comprised of 420 participants and was complemented by an observational arm, G6PD activity was only measured in the selected cohort
** from literature in Bangladesh [23] and calculated from convalescent subset in Indonesia and Ethiopia